{\rtf1\ansi\deff0
{\fonttbl{\f0\fswiss Arial;}{\f1\froman Times New Roman;}}
{\colortbl;\red0\green0\blue0;\red44\green62\blue80;\red127\green140\blue141;}
\f1\fs24

{\b\fs32\cf2 Longitudinal Patient-Reported Outcome Trajectories in Long COVID: Findings From the STOP-PASC Clinical Trial.}
\par\par

{\b Paper ID:} PMC12560753
\par
{\b Authors:} Jagannathan P, Hedlin H, Liang JW, Shaw B, Maestri E, Lin M, Utz PJ, Singh U, Geng LN, Bonilla H.
\par
{\b Journal:} Unknown
\par
{\b Year:} 2025
\par
{\b DOI:} 10.1093/ofid/ofaf634
\par\par

{\b\fs28 Abstract}
\par
<h4>Background</h4>Long COVID is a heterogeneous post-infectious condition. Although patient-reported outcome (PRO) measures for diagnosis or therapeutic monitoring have been adapted from related complex chronic illnesses, no PRO has been validated specifically in Long COVID. The STOP-PASC randomized, placebo-controlled trial of nirmatrelvir/ritonavir (NMV/r) in adults with Long COVID showed no overall treatment effect. This exploratory analysis aimed to identify distinct symptom trajectories and clinical characteristics associated with improvement or worsening over time.<h4>Methods</h4>We performed latent class trajectory modeling (LCTM) on PRO measures-including the Patient Global Impression of Severity (PGIS), Patient Global Impression of Change (PGIC), PROMIS domains, and core symptoms-among 155 randomized participants. Participants were followed for 15â€…weeks with serial symptom assessments. Trajectory groups were identified using Bayesian Information Criteria and characterized using descriptive statistics and absolute standardized differences.<h4>Results</h4>LCTM revealed heterogeneity in symptom trajectories. Two groups emerged for PGIS (improving <i>n</i> = 17, persistent/severe <i>n</i> = 136) and PGIC (improving <i>n</i> = 130; worsening <i>n</i> = 22). PROMIS-Physical Function modeling identified four groups (improving, normal/mild, moderate, and severe), fatigue core symptom modeling identified three (improving; moderate; severe). Worsening groups had higher proportions of NMV/r-treated participants and greater prevalence of cardiovascular symptoms and low-dose naltrexone use. Improving groups had shorter time since infection and higher baseline physical function. No subgroup showed a clear benefit from NMV/r.<h4>Conclusions</h4>Distinct PRO trajectories reflect the clinical heterogeneity of Long COVID. NMV/r showed no clear benefit across subgroups. These findings emphasize the need for validated, Long COVID-specific PRO instruments and targeted therapeutic trials tailored to Long COVID subtypes.
\par\par

{\i\fs18\cf3 Downloaded from Europe PMC | Full metadata available in JSON file}
}